News

Our ophthalmology month in review for September 2023 highlights our top stories in retina, the latest news from the FDA, and insights into the evolving specialty landscape.

The author of the largest clinical trial for pediatric PFIC to date discusses the various benefit maralixibat provides to disease managementr.

A new review and analysis suggests a combination treatment regimen for children in acute liver failure due to autoimmune hepatitis may help them maintain native liver survival.

Pooled phase 3 data presented at NASPGHAN 2023 support the benefit-risk profile of the IBAT inhibtor in treating the rare liver disease.

Results demonstrated comparable safety, immunogenicity, and pharmacokinetics between adalimumab-afzb and the reference product.

Annualized costs for the 24-month study period were highest among patients with both NASH and T2D, highlighting the incremental cost of adding an additional diagnosis for comorbid NASH or T2D.

Parents in the active disease group indicated greater levels of anxiety than parents of children without active IBD, suggesting a correlation between parental mental health and their child’s disease activity.

The rheumatology month in review highlights top data from the 2023 CCR West, CBT for reducing pain catastrophizing in patients with fibromyalgia, and the link between gout and a reduced likelihood of Alzheimer Disease.

This new synthetic data set could work as a potential resource for training on AI as well as to help facilitate a consensus among clinicians.

This installment in our Unprevented series examines the growing impact of chronic kidney disease on public health and what those in the field are doing to mitigate this growing crisis.

A new initiative from the HFSA highlights key findings on heart failure prevalence, risk, mortality and hospitalization rates in the United States.

The biosimilar month in review highlights an interview with leading experts, the latest data regarding switching between biologics and biosimilars, and the efficacy of infliximab biosimilars among patients with inflammatory conditions.

Phase 1/2 trial data shows all patients with T1D treated with VX-880 achieved improved glycemic control and a reduction or elimination of external insulin needs.

Amid the escalating threat of wildfires due to climate change, the medical and public health communities face an increasing responsibility to develop robust emergency response plans to safeguard patients and healthcare infrastructure.

Investigators found intestinal permeability and fecal and plasma metabolomic profiles of patients with PsA in the FLORA trial cohort were associated with clinical response to FMT.

In a new study, 50% of adolescents admitted into a psychiatric hospital screened positive for insomnia.

Patients aged less than 45 years at NAFLD onset had a higher risk of cancer compared to older age groups, highlighting an association between younger age at NAFLD onset and cancer risk.

Our endocrinology month in review for September 2023 spotlights news related to semaglutide and a pair of articles offering a deep dive into comorbidities in type 1 and type 2 diabetes.

Nondiabetic and diabetic patients without retinopathy experience similar results after treatment with an intravitreal dexamethasone implant for pseudophakic macular edema.

The COVID-19 pandemic skyrocketed already high rates of alcohol consumption and related liver disease to unprecedented levels. Addiction specialists and hepatologists are still looking for the best path out.

The investigators of this new data note that integration using a standardized process which is EMR-based may be the next thing to move for, to better address the overreporting of penicillin allergy.

A systematic literature search reported an increase in both publications and cases of spinal gout.

Switching to intravitreal dexamethasone improves visual outcomes, but does not significantly change subfoveal choroidal thickness or the choroidal vascularity index.

This interview segment with Dr. Harris-Tryon further explored some of the key points made in her upcoming talk regarding the microbiology of hidradenitis suppurativa.

At week 16, no significant differences in response rates were observed regarding the adalimumab biologic and biosimilars.

Interim results from the phase 3 APPLAUSE-IgAN study showed a statistically significant reduction in proteinuria among patients treated with iptacopan compared to placebo.

A new study from Sweden is calling attention to disproportionate increases in psychotropic medication use among young people with type 1 diabetes relative to their counterparts without type 1 diabetes.

Findings from a meta-analysis are calling attention to the viability of classification and risk stratification using greater albuminuria and decreased eGFR.

Investigators of a new meta-analysis designed the Psymatik Treatment Optimizer, an online tool which synthesizes side-effects in a database and can personalize individual user side effect concerns.

Among a cohort of young patients with no major comorbidity burdens, 49% were not waitlisted within 5 years of dialysis initiation.